iTeos CEO on making noise in busy IO field

Michel Detheux, CEO of iTeos Therapeutics, chats with Mike Ward, global director of content for Informa Pharma Insights, about the emerging company's pipeline of immuno-oncology therapeutics. Over the last two years, in Europe alone, around 50 IO startups have been created —but the challenge now for businesses in this R&D space is how to differentiate from the competition. Based in Belgium, iTeos was founded in 2012; Detheux talks about how the company, which has an IDO1 inhibitor in Phase I that is partnered with US pharma giant Pfizer, is getting attention in this crowded market.